FIGURE 2.

DDOST+/−Pod‐Cre mice exhibited a rapid and progressive decline in kidney function independent of macroalbuminuria. (A) Calculated GFR using the transcutaneous decay of retro‐orbitally injected FITCsinistrin. (B) Change in GFR, which was determined from matched GFR values from week 0 of the study (6–8 weeks of age) to week 12 of the study. Serum and 24‐h urine were collected from mice in metabolic cages at week 0 and week 12 of the study. (C‐E) Creatinine was measured spectrophotometrically at 550nm in a biochemical analyser. (C) Serum creatinine measured at week 12 of the study. (D) Ratio of creatinine clearance following correction for kidney weight measured at week 12 of the study. (E) Change in creatinine clearance, which was determined from matched creatinine clearance values from week 0 of the study (6–8 weeks of age) to week 12 of the study. (F‐G) Albumin was measured spectrophotometrically at 620nm in a biochemical analyser and the albumin excretion rate (AER) was determined based on the 24‐hour urine flow rate. (F) AER measured at week 12 of the study. (G) Change in albuminuria over the study, which was determined from matched albuminuria values from week 0 (6–8 weeks of age) of the study to week 12 of the study. Results are expressed as mean ± SD with either two‐way ANOVA or paired t‐test analysis (n = 3–8) *p < .05, **p < .01, ***p < .001